HLA-A2 melanoma patients with : 
either loco-regional or lymph node metastasis 
transit nodules not surgically resectable 
measurable cutaneous or visceral metastasis 
Patients' tumor express Melan-A/MART-1 antigen. 
No chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy in the last 4 weeks before infusion. 
No other melanoma treatment during the protocol. 
Life expectancy should be greater than 6 months. 
General state with Karnowsky greater than 80, ECOG = 0, 1 or 2. 
Patient should be negative for HIV and B and C hepatitis. 
Biological parameters at the beginning of the study: leucocytes ³ 2000 elements per mm3, hemoglobin ³ 10.5g/dl, platelets ³ 100 000 per mm3, phosphatases alcalines transaminases £ 1 time 1/2 compared to the normal. 
Signed informed consent 

NCT00720031_inc_T1
Condition
melanoma
NCT00720031_inc_T2
Qualifier
HLA-A2
NCT00720031_inc_T3
Condition
loco-regional metastasis
NCT00720031_inc_T4
Condition
lymph node metastasis
NCT00720031_inc_T5
Condition
transit nodules
NCT00720031_inc_T6
Qualifier
surgically resectable
NCT00720031_inc_T7
Negation
not
NCT00720031_inc_T8
Procedure
surgically
NCT00720031_inc_T9
Condition
visceral metastasis
NCT00720031_inc_T10
Condition
cutaneous metastasis
NCT00720031_inc_T11
Qualifier
measurable
NCT00720031_inc_T12
Scope
cutaneous or visceral metastasis
NCT00720031_inc_T13
Observation
MART-1 antigen
NCT00720031_inc_T14
Observation
Melan-A antigen
NCT00720031_inc_T15
Procedure
chemotherapy
NCT00720031_inc_T16
Negation
No
NCT00720031_inc_T17
Drug
Deticene
NCT00720031_inc_T18
Negation
except for
NCT00720031_inc_T19
Temporal
before the first T cell clones infusion
NCT00720031_inc_T20
Reference_point
the first T cell clones infusion
NCT00720031_inc_T21
Procedure
radiotherapy
NCT00720031_inc_T22
Procedure
immunotherapy
NCT00720031_inc_T23
Temporal
in the last 4 weeks before infusion
NCT00720031_inc_T24
Reference_point
infusion
NCT00720031_inc_T25
Condition
melanoma
NCT00720031_inc_T26
Temporal
during the protocol
NCT00720031_inc_T27
Procedure
treatment
NCT00720031_inc_T28
Observation
Life expectancy
NCT00720031_inc_T29
Value
greater than 6 months
NCT00720031_inc_T30
Measurement
Karnowsky
NCT00720031_inc_T31
Value
greater than 80
NCT00720031_inc_T32
Measurement
ECOG
NCT00720031_inc_T33
Value
0, 1 or 2
NCT00720031_inc_T34
Measurement
HIV
NCT00720031_inc_T35
Value
negative
NCT00720031_inc_T36
Measurement
C hepatitis
NCT00720031_inc_T37
Measurement
B hepatitis
NCT00720031_inc_T38
Scope
HIV and B and C hepatitis
NCT00720031_inc_T39
Measurement
leucocytes
NCT00720031_inc_T40
Value
³ 2000 elements per mm3
NCT00720031_inc_T41
Measurement
hemoglobin
NCT00720031_inc_T42
Value
³ 10.5g/dl
NCT00720031_inc_T43
Measurement
platelets
NCT00720031_inc_T44
Value
³ 100 000 per mm3
NCT00720031_inc_T45
Measurement
phosphatases alcalines transaminases
NCT00720031_inc_T46
Value
£ 1 time 1/2 compared to the normal
NCT00720031_inc_T47
Observation
Signed informed consent
NCT00720031_inc_T48
Scope
chemotherapy treatment (except for Deticene used before the first T cell clones infusion) or radiotherapy or immunotherapy
NCT00720031_inc_T49
Temporal
at the beginning of the study
NCT00720031_inc_T50
Reference_point
the beginning of the study
NCT00720031_inc_T51
Scope
leucocytes ³ 2000 elements per mm3, hemoglobin ³ 10.5g/dl, platelets ³ 100 000 per mm3, phosphatases alcalines transaminases £ 1 time 1/2 compared to the normal